C4 Therapeutics, Inc. · NASDAQ:CCCC
C4 Therapeutics — Investor Presentation (October 2024)
30 slides from C4 Therapeutics's investor presentation, October 2024
Slide 1: Protein degraded. Disease targeted. Lives transformed.
Protein degraded. Disease targeted. Lives transformed. October 2024
Slide 2: Forward-looking Statements and Intellectual Property
Forward-looking Statements and Intellectual Property Forward-looking Statements The following presentation contains forward-looking statements. All statements other than statements of historical fact are forward- looking statements, which are often indicated by terms such as “anticipate,” “believe,”
Slide 3: C4T Is a Recognized Leader in Delivering on the Promise of Targeted Protein Degradation
C4T Is a Recognized Leader in Delivering on the Promise of Targeted Protein Degradation WORLD-CLASS DEGRADER PLATFORM Robust patent portfolio of novel cereblon binders; Demonstrated ability to design orally bioavailable, catalytically efficient degraders Our Mission RIGOROUS TARGET SELECTION To deli
Slide 4: Designed and Advanced Degraders Into the Clinic Across a Range of Target Classes
Designed and Advanced Degraders Into the Clinic Across a Range of Target Classes, Demonstrating Robust Target Degradation Interrogated Diverse Attained IND Achieved Desirable Degraded Target as Target Classes Clearance Drug-like Properties Predicted Discovered degraders and advanced 4 INDs against a
Slide 5: Advancing a Broad Pipeline to Deliver Near-Term Value
Advancing a Broad Pipeline to Deliver Near-Term Value Early Phase Late Phase Program Target Indications Discovery Preclinical Rights Development Development Multiple Myeloma & Cemsidomide IKZF1/3 Non-Hodgkin’s Lymphoma BRAF V600 CFT1946 V600 Mutant Cancers Mutant Non-Small Cell Lung CFT89191 EGFR L8
Slide 6: C4T is On Track to Achieve All 2024 Goals
C4T is On Track to Achieve All 2024 Goals, Progressing Multiple Clinical and Preclinical Programs ASH 2024 (Dec.): Present updated data from Phase 1 dose escalation +dex trial in R/R MM Cemsidomide ASH 2024 (Dec.): Present data from Phase 1 dose escalation monotherapy trial in R/R NHL IKZF1/3 By YE
Slide 7: Cemsidomide
Cemsidomide Targeting IKZF1/3 Multiple Myeloma (MM) & Non-Hodgkin’s Lymphoma (NHL)
Slide 8: IKZF1/3 Degradation Drives Three Distinct Areas of Hematopoietic Biology
IKZF1/3 Degradation Drives Three Distinct Areas of Hematopoietic Biology; Degrading IKZF1/3 Is a Validated Therapeutic Strategy in MM and NHL IKZF1 / IKZF3 Transcription Factors Drive MM and NHL Cell Activate Fully Regulate Hematopoietic Growth and Survival Differentiated T-cells Stem Cell Different
Slide 9: Cemsidomide Has the Potential to Address Multiple Opportunities Across MM and NHL
Cemsidomide Has the Potential to Address Multiple Opportunities Across MM and NHL Annual Market Size3 U.S. Unmet Needs Incidence 2023 20304 • Additional efficacious and tolerable agents that work well in combination regimens Multiple Myeloma ~36,0001 ~$21B ~$42B • Therapies that increase the durabil
Slide 10: Cemsidomide Phase 1 Dose Escalation Trial Design in R/R MM and R/R NHL
Cemsidomide Phase 1 Dose Escalation Trial’s Goal Is to Define the Safety Profile and Identify Signs of Anti-Tumor Activity in R/R MM and R/R NHL Phase 1 Dose Escalation Trial Endpoints R/R MM Monotherapy Primary: Dosing: QD 21 days on/7 days off • Safety and tolerability N=5 • Determine the maximum
Slide 11: Prior Data Demonstrated Cemsidomide as a Potential MM Therapy
Prior Data Demonstrated Cemsidomide as a Potential MM Therapy + Established Safety Profile Demonstrated Promising Responses with and Dosing Schedule Monotherapy Activity Cemsidomide + Dexamethasone Cemsidomide is a potential treatment for multi-refractory MM patients with the ability to move into ea
Slide 12: Clinical Evidence of Immune T-cell Activation With Cemsidomide Monotherapy
Clinical Evidence of Immune T-cell Activation With Cemsidomide Monotherapy Supports potential of cemsidomide % positive cells (C1D21 vs C1D1) as a maintenance therapy option 100 C1D1 **** C1D21 and in combination with novel MM agents to improve efficacy: 80 ** ✓ Cemsidomide induces CD8+ T- % positiv
Slide 13: Cemsidomide Combined With Novel MM Agents Demonstrated Enhanced Immune Cell Lysis
Cemsidomide Combined With Novel MM Agents Demonstrated Enhanced Immune Cell Lysis in Non-clinical Translational Models Daratumumab (Anti-CD38) Combo Teclistamab (BCMA BiTE) Combo Antibody-Dependent Cell-Mediated Cytotoxicity Assay T-cell Dependent Cellular Cytotoxicity Assay (ADCC) (TDCC) Daratumuma
Slide 14: Cemsidomide + Dexamethasone Dose Escalation in R/R MM Continues to Progress
Cemsidomide + Dexamethasone Dose Escalation in R/R MM Continues to Progress KEY INCLUSION CRITERIA • Adults with R/R MM, at Phase 1: Dose Escalation + Dexamethasone Phase 2 least 3 prior lines that 14 Days On/14 Days Off have included lenalidomide, Potential for future dose escalation pomalidomide,
Slide 15: Cemsidomide + Dexamethasone Is Well Tolerated and Shows Best Responses
Cemsidomide + Dexamethasone Is Well Tolerated and Shows Best Responses in Patients Refractory to BCMA Therapies, Updated Data to be Presented at ASH Anti-myeloma Activity: Prior Dosing EMD # of Prior Cycle Cycle Cycle Cycle Cycle Cycle Cycle Cycle Cycle Cycle Cycle Dose Level CAR-T 1 2 3 4 5 6 7 8 9
Slide 16: Cemsidomide Profile Supports Multiple Opportunities Across MM Landscape
Cemsidomide Profile Supports Multiple Opportunities Across MM Landscape Potential Data Development Path Potential Opportunity Cemsidomide + Cemsidomide Accelerated Approval in Dexamethasone + Dexamethasone Multi-Refractory MM Registrational Study + PI Studies Approvals in Early Line MM + Anti-CD38 S
Slide 17: Cemsidomide Monotherapy Dose Escalation in R/R NHL Continues to Progress
Cemsidomide Monotherapy Dose Escalation in R/R NHL Continues to Progress, Initial Data to be Presented at ASH KEY INCLUSION CRITERIA • Adults with R/R NHL, with minimum prior Phase 1: Dose Escalation Monotherapy lines of therapy required for each NHL 14 Days On/14 Days Off sub-type: – PTCL: At least
Slide 18: CFT1946
CFT1946 Targeting BRAF V600 Mutant Melanoma, Colorectal (CRC) & Non-Small Cell Lung Cancer (NSCLC)
Slide 19: CFT1946 Has the Potential to Overcome Several Shortcomings Seen With BRAF Inhibitors
CFT1946 Has the Potential to Overcome Several Shortcomings Seen With Inhibitors for BRAF V600X Cancers Key Limitations of Approved BRAF Potential Advantages of CFT1946, a Novel, Inhibitors: Oral, BRAF V600 Mutant BiDAC degrader: • Durable and deep responses are often Despite limitations, ✓ Prevents
Slide 20: Kpu,u Results Demonstrate CFT1946's Ability to Cross the Blood Brain Barrier
Kpu,u Results Demonstrate CFT1946’s Ability to Cross the Blood Brain Barrier and Supports Activity in Preclinical Intercranial Metastatic Models A375 BRAF V600E-Luc Intracranial Model Survival Luminescence Per Mouse A375 BRAF V600E-Luc Intracranial Model Luminescence Luminescence Per Mouse Per Mouse
Slide 21: CFT1946 Phase 1/2 Dose Escalation Trial Continues to Progress
CFT1946 Phase 1/2 Dose Escalation Trial Continues to Progress Across BRAF V600 Mutant Driven Solid Tumors KEY INCLUSION MONOTHERAPY DOSE PK, PD, ANTI-TUMOR 2 Exploratory Expansion: CRITERIA1 ESCALATION ACTIVITY EVALUATION CFT1946 monotherapy in melanoma • Evidence of BRAF V600 Potential for further
Slide 22: CFT1946 Monotherapy Phase 1 Data Demonstrate Proof of Mechanism
CFT1946 Monotherapy Phase 1 Data Demonstrate Proof of Mechanism and Provide Early Evidence of Proof of Degrader Concept Proof of Mechanism Proof of Degrader Concept Well tolerated and highly Early evidence of monotherapy CFT1946 has the selective degrader, results in no anti-tumor activity in patien
Slide 23: Well-Tolerated Monotherapy Safety Profile of CFT1946
Well-Tolerated Monotherapy Safety Profile, Consistent With BRAF V600 Mutant Selectivity Design of CFT1946 Summary of TEAEs ≥ 10% of 36 patients treated with CFT1946 Grade 1 Grade 2 Grade 3 Grade 4 Grade 5 Total (n=36) Preferred Term n (%) n (%) n (%) n (%) n (%) n (%) • No DLTs Patients with any TEA
Slide 24: Early Signs of Anti-tumor Activity: 59% Patients Demonstrated Tumor Reductions
Early Signs of Anti-tumor Activity: 59% (16/27) Patients Demonstrated Target Lesion Tumor Reductions With 11 Efficacy Evaluable Patients Continuing Treatment * (As of 7/19/2024) V600R V600K V600K SD SD SD PR SD PD 5 SD PR 4 SD PR # 3 2 PD 1 PR *Other tumor types include cholangiocarcinoma, non-small
Slide 25: CFT1946 Has the Potential to Address Multiple Tumor Types With BRAF V600X Mutations
CFT1946 Has the Potential to Address Multiple Tumor Types With BRAF V600X Mutations Where BRAF Inhibitors Are Insufficient BRAF V600X 2023 U.S. Incidence of Approved BRAF Inhibitor Mutation Rate BRAF V600X Patients4 BRAF Inhibitors Regimen mPFS5 • Dabrafenib 1 • Encorafenib 11.4 months ~35% ~35,000
Slide 26: CFT8919
CFT8919 Targeting EGFR L858R Non-Small Cell Lung Cancer (NSCLC)
Slide 27: Potential for CFT8919 to Improve Outcomes for NSCLC Patients With EGFR L858R Mutations
Potential for CFT8919 to Improve Outcomes for NSCLC Patients With EGFR L858R Mutations Strong Rationale for an EGFR L858R Degrader CFT8919 Key Properties • Orally bioavailable • Potent and selective against L858R, EGFRL858R regardless of secondary mutations 1L • Allosteric binding osimertinib 1st-ge
Slide 28: CFT8919 is a Potent, Oral, Allosteric, Mutant-selective Degrader of EGFR L858R
CFT8919 is a Potent, Oral, Allosteric, Mutant-selective Degrader of EGFR L858R • CFT8919 exploits allosteric binding site, close CFT8919 to L858R activating mutation • Allosteric binding site avoids known Orthosteric resistance-causing mutations in orthosteric Inhibitor binding site • Allosteric bin
Slide 29: CFT8919 is Selective for EGFR L858R and Active in Osimertinib Resistance
CFT8919 is Selective for EGFR L858R and Active in a Setting of Osimertinib Resistance in Preclinical Models Specific for EGFR Exon 21 Mutants Active in setting of EGFR C797S Vehicle PO BID BaF3 EGFRL858R/T790M/C797S 2000 Osimertinib 25 mpk PO QD Tumor volume (mm3) CFT8919 10 mpk PO BID EGFR-L861Q CF
Slide 30: C4T is On Track to Achieve All 2024 Goals
C4T is On Track to Achieve All 2024 Goals, Progressing Multiple Clinical and Preclinical Programs ASH 2024 (Dec.): Present updated data from Phase 1 dose escalation +dex trial in R/R MM Cemsidomide ASH 2024 (Dec.): Present data from Phase 1 dose escalation monotherapy trial in R/R NHL IKZF1/3 By YE
C4 Therapeutics — Investor Presentation (October 2024) on 6ix